← Leaderboards
Roberta M O'Connor
Tufts Medical Center
$5,231,388
Attributed
$6,193,823
Total exposure
15
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $780.4K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,356,980 · 16
By mechanism
R21$3,591,789 · 8
R01$2,049,267 · 1
K01$389,610 · 1
S10$326,314 · 6
Top collaborators
- Nancy P Keller2 shared
- Laura J Knoll2 shared
- Christine E Salomon2 shared
- Clay C Wang2 shared
- Amy E Wright2 shared
Most similar at Tufts Medical Center
Same institution · by research overlap
- Honorine D Ward$12,801,535
Others in their field
Top investigators on “Cryptosporidium”
- Boris Striepen · University Of Pennsylvania$19,217,276
- Wesley C Van Voorhis · University Of Washington$13,225,240
- L David Sibley · Washington University$12,599,111
- Glenn D Kuehn · New Mexico State University Las Cruces$11,075,210
- Saul R Tzipori · Tufts University Boston$11,040,087
- Honorine D Ward · Tufts Medical Center$10,675,138
Research focus
CryptosporidiumParasitesCellsPathogenInfectionCryptosporidiosisAcquired Immunodeficiency SyndromeImmunocompromised HostPharmaceutical PreparationsDiarrheaInvestigationWaterborneStructureCryptosporidium ParvumFutureIntestinesEffective TherapyDeveloping CountriesGrowthIn VivoMedicalImmuneBacteriaAntiparasitic Agents
Grant awards (31)
Molecular targets of the anti-apicomplexan compound, tartrolon E$423,500
R21 · FY2025 · AI · contact PI
Development of a new marine natural product for the treatment of cryptosporidiosis, an AIDS-defining disease$370,533
R01 · FY2024 · AI · contact PI
Antiparasitic metabolites from deep subterranean fungi for the treatment of cryptosporidiosis, an AIDS defining disease$232,500
R21 · FY2024 · AI
Development of a new marine natural product for the treatment of cryptosporidiosis, an AIDS-defining disease$351,323
R01 · FY2023 · AI · contact PI
Cryptosporidium's polyketide secondary metabolite: exogenous production, compound characterization and function in intracellular development.$235,357
R21 · FY2023 · AI · contact PI
Antiparasitic metabolites from deep subterranean fungi for the treatment of cryptosporidiosis, an AIDS defining disease$193,750
R21 · FY2023 · AI
Development of a new marine natural product for the treatment of cryptosporidiosis, an AIDS-defining disease$424,141
R01 · FY2022 · AI · contact PI
Cryptosporidium's polyketide secondary metabolite: exogenous production, compound characterization and function in intracellular development.$224,014
R21 · FY2022 · AI · contact PI
Development of a new marine natural product for the treatment of cryptosporidiosis, an AIDS-defining disease$429,156
R01 · FY2021 · AI · contact PI
Development of a new marine natural product for the treatment of cryptosporidiosis, an AIDS-defining disease$474,114
R01 · FY2020 · AI · contact PI
Discovery of Marine Natural Products Effective against the AIDS associated pathogen Cryptosporidium$189,063
R21 · FY2019 · AI · contact PI
Discovery of Marine Natural Products Effective against the AIDS associated pathogen Cryptosporidium$240,387
R21 · FY2018 · AI · contact PI
RNAseq analyses in immunocompromised and immune competent mice infected with the AIDS pathogen Cryptosporidium$204,243
R21 · FY2017 · AI · contact PI
Investigation of a shipworm endosymbiont compound with activity against the AIDS-associated pathogens Cryptosporidium and Toxoplasma$190,000
R21 · FY2017 · AT · contact PI
Investigation of a shipworm endosymbiont compound with activity against the AIDS-associated pathogens Cryptosporidium and Toxoplasma$270,988
R21 · FY2016 · AT · contact PI
RNAseq analyses in immunocompromised and immune competent mice infected with the AIDS pathogen Cryptosporidium$252,433
R21 · FY2016 · AI · contact PI
Investigation of a shipworm endosymbiont compound with activity against the AIDS-associated pathogens Cryptosporidium and Toxoplasma$6,594
R21 · FY2016 · AT · contact PI
T. gondii as a model for investigation of Cryptosporidium glycoprotein antigens$199,238
R21 · FY2010 · AI · contact PI
T. gondii as a model for investigation of Cryptosporidium glycoprotein antigens$90,725
R21 · FY2010 · AI · contact PI
T. gondii as a model for investigation of Cryptosporidium glycoprotein antigens$241,500
R21 · FY2009 · AI · contact PI
Role of Cryptosporidium Mucins in Host-parasite interactions$195,414
R21 · FY2007 · AI · contact PI
Role of Cryptosporidium Mucins in Host-parasite interactions$202,083
R21 · FY2006 · AI · contact PI
ZEISS AXIOPLAN 2 IMAGING SYSTEM$163,157
S10 · FY2005 · RR
Gut Epithelial Cell Receptors for C parvum Invasion$129,870
K01 · FY2005 · DK
ZEISS AXIOPLAN 2 IMAGING SYSTEM: CELL BIOLOGY$73,420
S10 · FY2005 · RR
ZEISS AXIOPLAN 2 IMAGING SYSTEM: CPNEUMONIAE, SHIGA TOXIN, CPARVUM$32,631
S10 · FY2005 · RR
ZEISS AXIOPLAN 2 IMAGING SYSTEM: BBURGDORFERI, LYME DISEASE$24,474
S10 · FY2005 · RR
ZEISS AXIOPLAN 2 IMAGING SYSTEM: PANCREATIS, PULMONARY HYPERTENSION,$16,316
S10 · FY2005 · RR
ZEISS AXIOPLAN 2 IMAGING SYSTEM: CARDIOVASCULAR RESEARCH$16,316
S10 · FY2005 · RR
Gut Epithelial Cell Receptors for C parvum Invasion$129,870
K01 · FY2004 · DK
Gut Epithelial Cell Receptors for C parvum Invasion$129,870
K01 · FY2003 · DK